Filing Flows › Johnson & Johnson (JNJ) › Q3 2026 › vs Q2 2026
Johnson & Johnson (JNJ) Q3 2026 vs Q2 2026 (quarter over quarter)
Johnson & Johnson's revenue rose $89.0M (+0.4%) from $25.3B in Q2 2026 to $25.4B in Q3 2026. The biggest changes: Innovative Medicine +$373M (+2%); MEDTECH −$284M (-3%). Gross margin 68.1% against 68.2% (-0.1 pts).
Johnson & Johnson, Q3 2026: revenue $25.4B (+6% year over year), operating margin 0.1%, net earnings $210M, operating cash flow $7.7B. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 68.1% | 68.2% | -0.1 pts |
| Operating margin | 0.1% | 26.7% | -26.5 pts |
| Net margin | 0.8% | 21.9% | -21.0 pts |
| Free cash flow margin | 25.0% | 28.8% | -3.8 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Innovative Medicine | $16.8B | $16.4B | $373M | +2% |
| MEDTECH | $8.6B | $8.9B | −$284M | -3% |
| Revenue | $25.4B | $25.3B | $89.0M | +0.4% |
| Gross profit | $17.3B | $17.3B | $43.0M | +0.2% |
| Cost of revenue | $8.1B | $8.1B | $46.0M | +0.6% |
| Operating profit | $34.0M | $6.7B | −$6.7B | -99% |
| Operating expenses | $17.3B | $10.5B | $6.8B | +64% |
| Pre-tax earnings | $34.0M | $6.7B | −$6.7B | -99% |
| Research & development | $4.7B | $3.7B | $999M | +27% |
| SG&A | $6.3B | $6.4B | −$147M | -2% |
| Other operating costs | $6.3B | $427M | $5.9B | 15× |
| Income tax benefit | $176M | −$1.2B | $1.4B | — |
| Net earnings | $210M | $5.5B | −$5.3B | -96% |
| Depreciation & amortization | $2.1B | $2.0B | $158M | +8% |
| Share-based compensation | $357M | $458M | −$101M | -22% |
| Working capital & other | $5.0B | $665M | $4.4B | +657% |
| Operating cash flow | $7.7B | $8.6B | −$896M | -10% |
| Free cash flow (OCF − capex) | $6.4B | $7.3B | −$937M | -13% |
| Capital expenditures | $1.4B | $1.3B | $41.0M | +3% |
Questions
How much did Johnson & Johnson's revenue grow quarter over quarter in Q3 2026?
Johnson & Johnson's revenue rose $89.0M (+0.4%) from $25.3B in Q2 2026 to $25.4B in Q3 2026.
What drove Johnson & Johnson's revenue change in Q3 2026?
Innovative Medicine +$373M (+2%); MEDTECH −$284M (-3%).